Paxalisib blocks the PI3K/mTOR pathway, which plays a role in cancer cell growth and survival, but researchers have also ...

Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.

Interrupting one function of a protein that plays a key role in cell signaling could enable the development of new cancer treatments, according to a study led by Dr. Martin Taylor at the Warren Alpert ...

To read the full story, subscribeor sign in. Cancer SRRM2 drives colorectal cancer growth by a dual mTOR regulation March 11, 2025 Scientists at Southern University of Science and Technology in ...

The PAM pathway drives breast cancer growth and mediates resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i). Combining PAM inhibition with ET plus CDK4/6i after progression may ...

Cellular senescence has long been portrayed as one of the body’s most dependable defenses against cancer. When a cell’s telomeres wear down, when an oncogene such as RAS or BRAF fires abnormally, or ...